Title of article
Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study
Author/Authors
Alexandre C Linhares، نويسنده , , F Ra?l Velazquez، نويسنده , , Irene Perez-Schael، نويسنده , , Xavier Saez-Llorens، نويسنده , , Hector Abate، نويسنده , , Felix Espinoza، نويسنده , , Pio Lopez، نويسنده , , Mercedes Macias-Parra، نويسنده , , Eduardo Ortega-Barria، نويسنده , , Doris Maribel Rivera-Medina، نويسنده , , Luis Rivera، نويسنده , , Noris Pavia-Ruz، نويسنده , , Ernesto Nu?ez، نويسنده , , Silvia Damaso، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
9
From page
1181
To page
1189
Abstract
Background
Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. We therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenterit
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
592719
Link To Document